A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Response of Repeated Subcutaneous Doses of E1 in Combination With G1 in Patients With Type 2 Diabetes
Sponsor: OPKO Health, Inc.
This PHASE1 trial investigates Type 2 Diabetes and is currently completed. OPKO Health, Inc. leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Oct 2019 — Nov 2019 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Jun 2018 — Oct 2019 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Sep 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- OPKO Health, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .